DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

DIGITAL CONTENT

5 NEWS #PharmaBuzz

media
5 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1702816-75-8, Pi3kdelta-in-2, Pi3k(delta)-in-2, 05hyk3cv9n, Yy-20394, Pi3k

Molecular Formula

C₂₈H₃₇FN₆O₅S

Molecular Weight

588.7 g/mol

InChI Key

NVWKNQGHVMMAJW-UHFFFAOYSA-N

FDA UNII

05HYK3CV9N

Linperlisib is an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.

1 2D Structure

Linperlisib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[5-[6-fluoro-8-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-2-morpholin-4-ylquinazolin-4-yl]-2-methoxypyridin-3-yl]methanesulfonamide

2.1.2 InChI

InChI=1S/C28H37FN6O5S/c1-28(2,36)20-5-7-34(8-6-20)17-19-13-21(29)15-22-24(31-27(32-25(19)22)35-9-11-40-12-10-35)18-14-23(33-41(4,37)38)26(39-3)30-16-18/h13-16,20,33,36H,5-12,17H2,1-4H3

2.1.3 InChI Key

NVWKNQGHVMMAJW-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(C1CCN(CC1)CC2=C3C(=CC(=C2)F)C(=NC(=N3)N4CCOCC4)C5=CC(=C(N=C5)OC)NS(=O)(=O)C)O

2.2 Other Identifiers

2.2.1 UNII

05HYK3CV9N

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1702816-75-8

2. Pi3kdelta-in-2

3. Pi3k(delta)-in-2

4. 05hyk3cv9n

5. Yy-20394

6. Pi3k

7. A-in-2

8. N-[5-[6-fluoro-8-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-2-morpholin-4-ylquinazolin-4-yl]-2-methoxypyridin-3-yl]methanesulfonamide

9. Methanesulfonamide, N-(5-(6-fluoro-8-((4-(1-hydroxy-1-methylethyl)-1-piperidinyl)methyl)-2-(4-morpholinyl)-4-quinazolinyl)-2-methoxy-3-pyridinyl)-

10. N-(5-(6-fluoro-8-((4-(2-hydroxypropan-2-yl) Piperidin-1-yl)methyl)-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-)methanesulfonamide

11. Linperlisib [inn]

12. Pi3kd-in-2

13. Pi3ko-in-2

14. Unii-05hyk3cv9n

15. Pi3k.delta.-in-2

16. Linperlisib [who-dd]

17. Pi3k -in-2

18. Chembl4574601

19. Schembl18032489

20. Gtpl10466

21. Us9656996, Compound 10

22. Bdbm309960

23. Bcp20830

24. Ctc81675

25. Ex-a1436

26. Pi3k(c)(1/2)-in-2

27. Cs-6973

28. Yy20394

29. Compound 10 [us20160244432]

30. Yy-20394; Pi3k

31. A-in-2

32. Ac-35638

33. Hy-102031

34. N-[5-[6-fluoro-8-[[4-(1-hydroxy-1-methylethyl)-1-piperidinyl]methyl]-2-(4-morpholinyl)-4-quinazolinyl]-2-methoxy-3-pyridinyl]-methanesulfonamide

2.4 Create Date

2015-05-04

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₃₇FN₆O₅S
Molecular Weight	588.7 g/mol
XLogP3	2.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	8
Exact Mass	588.25301764 g/mol
Monoisotopic Mass	588.25301764 g/mol
Topological Polar Surface Area	138 Å²
Heavy Atom Count	41
Formal Charge	0
Complexity	958
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1